Tempus AI, Inc. (NASDAQ:TEM) CAO Sells $484,720.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CAO Ryan M. Bartolucci sold 6,059 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $80.00, for a total transaction of $484,720.00. Following the completion of the sale, the chief accounting officer now directly owns 47,000 shares of the company’s stock, valued at approximately $3,760,000. This trade represents a 11.42 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Tempus AI Price Performance

Shares of NASDAQ:TEM opened at $89.44 on Monday. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI, Inc. has a 52-week low of $22.89 and a 52-week high of $91.45. The stock’s fifty day simple moving average is $46.60 and its 200-day simple moving average is $50.37.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TEM. Kovitz Investment Group Partners LLC purchased a new stake in shares of Tempus AI in the third quarter valued at $1,367,000. China Universal Asset Management Co. Ltd. acquired a new stake in Tempus AI in the fourth quarter valued at approximately $1,091,000. Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Tempus AI by 1,591.2% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock valued at $68,922,000 after purchasing an additional 1,145,698 shares during the period. Captrust Financial Advisors acquired a new stake in Tempus AI during the 3rd quarter valued at $2,726,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Tempus AI during the 4th quarter valued at $178,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

TEM has been the subject of a number of research reports. Wolfe Research assumed coverage on Tempus AI in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. Guggenheim assumed coverage on Tempus AI in a research note on Monday, December 9th. They set a “buy” rating and a $74.00 target price for the company. Loop Capital reduced their price objective on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research note on Tuesday, January 14th. Needham & Company LLC reissued a “buy” rating and set a $56.00 price target on shares of Tempus AI in a research note on Tuesday, January 14th. Finally, Bank of America raised their price objective on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday, December 13th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Tempus AI has a consensus rating of “Moderate Buy” and an average price target of $58.55.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.